Why the study?
Does candesartan provide clinical benefit in patients with heart failure with or without left ventricular systolic dysfunction?
Does candesartan provide clinical benefit in patients with heart failure with or without left ventricular systolic dysfunction?
Candesartan is beneficial in heart failure patients across the spectrum of left ventricular systolic dysfunction, both as an alternative to and in addition to ACE inhibitors.
Supports candesartan across HF spectrum as alternative or add-on; extends evidence to preserved EF but leaves open prospective confirmation.
The large Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial recently found that in patients with heart failure who were similar to those whom clinicians see in everyday practice, the angiotensin-receptor blocker candesartan was not only an acceptable alternative to angiotensin-converting enzyme (ACE) inhibitors, but also was beneficial when added to regimens that already included ACE inhibitors and beta-blockers. Candesartan was beneficial in heart failure patients with or without left ventricular systolic dysfunction.
No takes yet. Share an insight, caveat, or question.
Bhakta et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: